Skip to Content

Petlife Pharmaceuticals Inc PTLF

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PTLF is trading at a 36% discount.
Price
$0.00
Fair Value
$6.00
Uncertainty
Extreme
1-Star Price
$5.79
5-Star Price
$4.70
Economic Moat
Hcs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTLF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.25
Market Cap
$19,675.17
Volume/Avg
10,000 / 69,056

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Total Number of Employees
1

Valuation

Metric
PTLF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
PTLF

Financial Strength

Metric
PTLF
Quick Ratio
0.00
Current Ratio
0.00
Interest Coverage
−5.88
Quick Ratio
PTLF

Profitability

Metric
PTLF
Return on Assets (Normalized)
−1,366.31%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
PTLF
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AJrgvswkblJfxfy$77.2 Bil
MKKGY
Merck KGaA ADRFyspsxytxKllhdjd$75.4 Bil
HLN
Haleon PLC ADRKcgdxgcGypjj$38.1 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRTzgfwvqxdNwzcz$16.0 Bil
VTRS
Viatris IncLrfsjjlcyJzn$14.0 Bil
RDY
Dr Reddy's Laboratories Ltd ADRJwqgbfjwLnz$12.1 Bil
CTLT
Catalent IncShrnqdddYwdmh$10.2 Bil
PRGO
Perrigo Co PLCHlhsvtgvbWgwns$4.3 Bil
CURLF
Curaleaf Holdings IncMyymsxzdbRvfz$4.0 Bil
PBH
Prestige Consumer Healthcare IncMkthcjhXfbwflz$3.6 Bil

Sponsor Center